Metabolic dysfunction-associated steatotic liver disease in people with HIV.

Review of metabolic liver disease in HIV patients, covering tesamorelin as a therapeutic option for reducing hepatic fat.

Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.

Clinical study examining tesamorelin's effects on neurocognitive function in HIV-positive individuals with abdominal obesity.

Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis.

Meta-analysis of RCTs evaluating tesamorelin's effects on body composition, liver fat, and metabolic outcomes in HIV-associated lipodystrophy.

Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.

Study evaluating tesamorelin's efficacy and safety in HIV patients receiving integrase inhibitor-based antiretroviral therapy.

Approach to the Patient With Lipodystrophy.

Clinical review covering diagnosis and management of lipodystrophy, including tesamorelin as an FDA-approved treatment.

Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach.

Mechanistic study identifying molecular pathways through which tesamorelin reduces liver fat in HIV-associated NAFLD.

Pharmacologic Treatments for the Preservation of Lean Body Mass During Weight Loss.

Review of pharmacological approaches to preserving lean mass during weight loss, including growth hormone-releasing peptides like tesamorelin.

The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets.

Preclinical study showing ipamorelin protects against cisplatin-induced weight loss.

Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.

Review of growth hormone secretagogues including ipamorelin for managing body composition in men with low testosterone.

Structure-activity relationship for peptidic growth hormone secretagogues.

Study examining structure-activity relationships of peptidic growth hormone secretagogues including ipamorelin.

Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.

Pharmacokinetic study characterizing urinary metabolites of ipamorelin after nasal administration in humans.

Metabolism of growth hormone releasing peptides.

Comprehensive study of metabolic pathways and breakdown products of growth hormone releasing peptides including ipamorelin.